Metabolism and effects of acetoaceto-<i>o</i>-toluidine in the urinary bladder of humanized-liver mice
Occupational exposure to aromatic amines is a major risk factor for urinary bladder cancer. Our previous studies showed that acetoaceto-<i>o</i>-toluidine, which is produced using <i>o</i>-toluidine as a raw material, promotes urinary bladder carcinogenesis in rats. We also found high concentrations of <i>o</i>-toluidine, a human bladder carcinogen, in the urine of acetoaceto-<i>o</i>-toluidine-treated rats, indicating that urinary <i>o</i>-toluidine derived from acetoaceto-<i>o</i>-toluidine may play an important role in bladder carcinogenesis. However, this has not been investigated in humans. In the present study, we used non-humanized (F1-TKm30 mice) and humanized-liver mice established by human hepatocyte transplantation to compare differences in urinary acetoaceto-<i>o</i>-toluidine metabolites produced by human and mouse liver cells. We also examined the changes in acetoaceto-<i>o</i>-toluidine-induced mRNA expression in the liver and the proliferative effects on the bladder epithelium. Urinary <i>o</i>-toluidine was detected in both non-humanized and humanized mice. Acetoaceto-<i>o</i>-toluidine metabolites in the urine, cell proliferation activities, and DNA damage in the bladder urothelium were similar in non-humanized and humanized-liver mice. RNA expression analysis revealed that CYP1A2 expression increased in the livers of humanized-liver mice, and Cyp2c29 expression (equivalent to human CYP2C9/19) increased in the livers of non-humanized mice. These data suggest that acetoaceto-<i>o</i>-toluidine may be a human carcinogen, as evidenced by the detection of urinary <i>o</i>-toluidine in acetoaceto-<i>o</i>-toluidine-treated humanized-liver mice. This animal model is important for extrapolating toxicity data from animals to humans.
Authors
- Min Gi (ORCID: https://orcid.org/0000-0003-1642-8127)
- Shugo Suzuki (ORCID: https://orcid.org/0000-0001-8938-9670)
- Masaki Fujioka (ORCID: https://orcid.org/0000-0003-0048-2874)
- Shigeki Koda (ORCID: https://orcid.org/0000-0002-0180-7848)
- Arpamas Vachiraarunwong (ORCID: https://orcid.org/0000-0002-0463-2289)
- Hiroshi Suemizu (ORCID: https://orcid.org/0000-0002-3706-2454)
- Yukie Yanagiba (ORCID: https://orcid.org/0000-0002-6261-840X)
- Ikue Noura (ORCID: https://orcid.org/0009-0005-5044-9054)
- Anna Kakehashi (ORCID: https://orcid.org/0000-0003-1149-1450)
- Nao Yoneda (ORCID: https://orcid.org/0009-0009-7696-5814)
- Shotaro Uehara (ORCID: https://orcid.org/0000-0002-1359-8828)
- Hideki Wanibuchi (ORCID: https://orcid.org/0000-0001-9362-4290)
- Yuka Yokota
Institutions
- Central Institute for Experimental Animals (JP)
- National Institute of Occupational Safety and Health (JP)
Publication Details
- Journal
- Journal of Toxicologic Pathology
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1293/tox.2024-0042
- Primary Topic
- Eicosanoids and Hypertension Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Society for the Promotion of Science